Detection of Variants With Reduced Baloxavir Marboxil Susceptibility After Treatment of Children With Influenza A During the 2018–2019 Influenza Season-Reference-Cited by-同舟云学术

Detection of Variants With Reduced Baloxavir Marboxil Susceptibility After Treatment of Children With Influenza A During the 2018–2019 Influenza Season

Published:2020-02-08 Issue:1 Volume:222 Page:121-125
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Sato Masatoki¹,Takashita Emi²,Katayose Masahiko³,Nemoto Kenji⁴,Sakai Nobuko⁵,Hashimoto Koichi¹,Hosoya Mitsuaki¹

Affiliation:

1. Department of Pediatrics, Fukushima Medical University, Fukushima, Japan

2. Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan

3. Nanohana Kids Clinic, Soma, Japan

4. Nemoto Kids Clinic, Shirakawa, Japan

5. Jin Kids Clinic, Koriyama, Japan

Abstract

Abstract During the 2018–2019 influenza seasons, we detected reduced baloxavir marboxil (baloxavir) susceptible variants with I38S or I38T amino acid substitutions on the PA subunit of influenza virus ribonucleic acid polymerase in 7 of 18 baloxavi-treated children and found that virus titer rebounded in some of these children with variants. We also found fever durations to be similar between patients with or without the variants, but the patients with variants shed the virus 3 days longer and took longer to improve clinical symptoms than those without variants. The emergence of these variants should be monitored during future influenza seasons.

Funder

Grant-in-Aid for Emerging and Reemerging Infectious Diseases

Ministry of Health, Labor and Welfare

JSPS KAKENHI

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiaa061/32666300/jiaa061.pdf

Reference15 articles.

1. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit;Noshi;Antiviral Res,2018

2. Baloxavir marboxil for uncomplicated influenza in adults and adolescents;Hayden;N Engl J Med,2018

3. Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza;Uehara;J Infect Dis,2020

4. Baloxavir marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes;Hirotsu;Clin Infect Dis,2019

5. Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018;Takashita;Euro Surveill,2019

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Detection of influenza A(H3N2) viruses with polymerase acidic subunit substitutions after and prior to baloxavir marboxil treatment during the 2022–2023 influenza season in Japan;Antiviral Research;2024-09

2. Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022–2023 season;Antiviral Research;2024-04

3. Prophylactic Treatment with Baloxavir Protects Mice from Lethal Infection with Influenza A and B Viruses;Viruses;2023-11-16

4. A community cluster of influenza A(H3N2) virus infection with reduced susceptibility to baloxavir due to a PA E199G substitution in Japan, February to March 2023;Eurosurveillance;2023-09-28

5. Early Fever Resolution in Early Childhood Influenza Treated with Baloxavir Marboxil: A Retrospective Study Compared to Those with Oseltamivir;Medicina;2023-08-25